Fig. 6

NT1721 displays better antitumor efficacy than gemcitabine and prolongs survival of mice with advanced pancreatic cancer. Male NSG mice were orthotopically implanted with Capan1 luc⁺ cells. Treatment started with 30 mg/kg NT1721 (three times per week), gemcitabine (100 mg/kg, twice per week) or the vehicle control (n = 7 per group) 12 days (a, b) or 25 days (d) after cell implantation. a Bioluminescent signals. The mice were imaged on the indicated days. The asterisk indicates a significant difference between the control group and treatment groups (NT1721 or gemcitabine) on day 25 (p < 0.05). b Tumor weight after 5 weeks of treatment with NT1721 or gemcitabine. P values were determined using Mann-Whitney test and are indicated in the graphs. c Photos of the representative primary tumors from mice that were treated with NT1721 or gemcitabine and euthanized after 5 weeks of treatment. d Survival curves. Treatment with NT1721 or gemcitabine started on day 25 after tumor implantation (n = 6). The log-rank test was used to determine p values: The difference in survival between the control and gemcitabine treated group was significant (p = 0.029); the difference between the gemcitabine-treated and the NT1721-treated group was also significant (p = 0.0007)